TRBV2
T cell receptor beta variable 2
Also known as: TCRBV22S1A2N1T, TCRBV2S1, TVB2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A0A1B0GX68
- Gene
- TRBV2
- Ensembl
- ENSG00000226660
- Chromosome
- 7
- Canonical length
- 115 aa
- Protein class
- Predicted intracellular proteins, T-cell receptor genes
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to be involved in cell surface receptor signaling pathway. Predicted to be part of T cell receptor complex. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
115 residues, UniProt reviewed canonical sequence.
>A0A1B0GX68|TRBV2
1 MDTWLVCWAI FSLLKAGLTE PEVTQTPSHQ VTQMGQEVIL RCVPISNHLY FYWYRQILGQ
61 KVEFLVSFYN NEISEKSEIF DDQFSVERPD GSNFTLKIRS TKLEDSAMYF CASSELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRBV2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Highest tissue expression
- 83 nTPM
Expression across tissuesHPA
Tissue
- thymus: 83 nTPM
- lymph node: 24 nTPM
- tonsil: 21 nTPM
- appendix: 7.8 nTPM
- spleen: 6.4 nTPM
- bone marrow: 3.7 nTPM
Single-cell type
- early spermatids: 0.1 nCPM
- t-cells: 0.1 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
Immune cell
- T-reg: 123 nTPM
- memory CD4 T-cell: 121 nTPM
- naive CD4 T-cell: 72 nTPM
- memory CD8 T-cell: 65 nTPM
- naive CD8 T-cell: 45 nTPM
- total PBMC: 29 nTPM
Brain region
- pons: 0.3 nTPM
- medulla oblongata: 0.2 nTPM
- basal ganglia: 0.1 nTPM
- cerebral cortex: 0.1 nTPM
- choroid plexus: 0.1 nTPM
- thalamus: 0.1 nTPM
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRBV2 as an antibody target. Whether an autoantibody or antibody against TRBV2 could matter depends on whether native TRBV2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRBV2 is annotated at the cell surface, where native TRBV2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRBV2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...